Mereo BioPharma Group GAAP EPS of -$0.04

• Mereo BioPharma Group press release (NASDAQ:MREO): FY GAAP EPS of -$0.04.
• As of December 31, 2023, the Company had cash and cash equivalents of $57.4 million. Net cash burn during the fourth quarter of 2023 amounted to $6.7 million.
• The Company’s guidance remains unchanged, and it continues to expect, based on current operational plans, that its existing cash and cash equivalents balance will enable it to fund its currently committed clinical trials, operating expenses, and capital expenditure requirements into 2026.
• This guidance does not include any potential upfront payments associated with a partnership for alvelestat or business development activity around any of the Company’s non-core programs.

More on Mereo BioPharma Group

• Mereo BioPharma provides update on pipeline progress, reaffirms cash runway guidance
• Seeking Alpha’s Quant Rating on Mereo BioPharma Group
• Historical earnings data for Mereo BioPharma Group
• Financial information for Mereo BioPharma Group